Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses

References

• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-37
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with Febrile Neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-24
   PubMed Web of Science ®Google Scholar
• Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Therapeut Med 2011;2:859-66
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008;16:1299-309
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-31
   PubMed Web of Science ®Google Scholar
• Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 2011;77:221-40
   PubMed Web of Science ®Google Scholar
• United States Department of Health & Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Published: May 28, 2009 (v4.03: June 14, 2010)
   Google Scholar
• von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008;19:292-8
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN), Inc. Clinical Practice Guidelines in Oncology: Myeloid Growth Factors Version 1.2012. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive. Accessed 1 August 2012
   Google Scholar
• Amgen, Inc. Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen, Inc.; 2011. http://pi.amgen.com/united_states/neulasta/neulasta_pi_hcp_english.pdf. Accessed August 28, 2011
   Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   PubMed Web of Science ®Google Scholar
• Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or Stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
   PubMed Web of Science ®Google Scholar
• Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003;21:2466-73
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tobinai K, Shibata T, et al. Phase II/III Study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-Cell non-hodgkin’s lymphoma: JCOG 0203 Trial. J Clin Oncol 2011;29:3990-8
   PubMed Web of Science ®Google Scholar
• Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 2009;25:401-11
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health 2009;12:217-25
   Google Scholar
• Ösby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840-8
   PubMed Web of Science ®Google Scholar
• Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007;12:1416-24
   PubMed Web of Science ®Google Scholar
• LePage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann Oncol 1993;4:651-6
   PubMed Web of Science ®Google Scholar
• Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008;87:277-83
   PubMed Web of Science ®Google Scholar
• Whyte S, Cooper KL, Stevenson MD, et al. Cost-Effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom. Value Health 2011;14:465-74
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-75
   PubMed Web of Science ®Google Scholar
• National Cancer Institute/Surveillance, Epidemiology, and End Results (SEER) database (SEER*Stat 6.5.1). Kaplan-Meier method, Survival Sessions, No adjustment for heterogeneity. Available from: http://seer.cancer.gov/seerstat/. Accessed February 25, 2009
   Google Scholar
• Arias E. United States life tables, 2007. National vital statistics reports; vol 59 no 9. Hyattsville, MD: National Center for Health Statistics, 2011
   Google Scholar
• Doorduijn JK, Buijt I, Van Der Holt B, et al. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2004;89:1109-17
   PubMed Web of Science ®Google Scholar
• Uyl-de-Groot CA, Hagenbeek A, Verdonck LF, et al. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 1995;16:463-70
   PubMed Web of Science ®Google Scholar
• Brown RE, Hutton J. Cost-Utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anti-Cancer Drugs 1998;9:899-907
   PubMed Web of Science ®Google Scholar
• Brown RE, Hutton J, Burrel A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 2001;19:1091-102
   PubMed Web of Science ®Google Scholar
• Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally representative values for the non-institutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006;26:391-400
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. 2012 Medicare Average Sales Price Drug Pricing File (Released June 7, 2012 for Quarter 3). Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2012ASPFiles.html. Accessed 25 July 2012
   Google Scholar
• Physician's Fee & Coding Guide 2012. Atlanta, GA: MAG Mutual Healthcare Solutions, Inc; 2012
   Google Scholar
• Doan QV, Gleeson M, Kim J, et al. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin 2007;23:1561-9
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Edelsberg J, et al. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008;19:454-60
   PubMed Web of Science ®Google Scholar
• Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in patients with small-cell lung cancer. J Clin Oncol 2006;24:2991-7
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Kartashov A, et al. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy 2012;58:8-18
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
   Google Scholar
• Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008;8:165-78
   PubMedGoogle Scholar
• Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med 2006;355:920-7
   PubMed Web of Science ®Google Scholar
• Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2009;114:479-84
   PubMed Web of Science ®Google Scholar
• Hanna RK, Poniewierski MS, Laskey RA, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2013;129:74-80
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Hanna RK, Poniewierski R, et al. Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer. J Clin Oncol 29: 2011 (suppl; abstr 5084)
   Google Scholar